Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Inclusion Criteria: 1. Personally submitted written voluntary informed consent to participate in the study 2. Aged ≧18 years at the time of consent 3. Stable chronic renal failure treated with hemodialysis 3 times weekly for at least 12 weeks before screening 4. Intact PTH level (centrally measured) of \>300 pg/mL at screening 5. Corrected serum Ca level (centrally measured) of ≧9.0 mg/dL at screening Exclusion Criteria: 1. Treatment with cinacalcet hydrochloride within 2 weeks before screening 2. Change in dose or dosing regimen of an activated vitamin D drug or its derivative, phosphate binder, or Ca preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening 3. Change in prescribed conditions of dialysis (dialysate Ca concentration, prescribed dialysis time, and prescribed number of dialysis per week) within 2 weeks before screening 4. Treatment with bisphosphonates, denosumab or teriparatide within 24 weeks before screening 5. Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening 6. Severe heart disease (e.g., ≧ Class Ⅲ per New York Heart Association classification) 7. Severe hepatic dysfunction (e.g., treatment with antiviral therapy) 8. Uncontrolled hypertension and/or diabetes